B
Bull
Bull · 25%EVOK
$6.43
Scenario price
$11.000
+0.040 (+0.36%)At close
Loading chart…
- High
- 11.000
- Open
- 10.980
- VWAP
- 10.99
- Vol
- 47.10K
- Mkt Cap
- 4.31M
- Low
- 10.980
- Amount
- 517.84K
- EV/EBITDA, TTM
- -0.01
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Analyst Ratings (5)
Buy
5 Buy
0 Hold
0 Sell
Current: 11.00
Low
—
Average
—
High
—
JPMorgan
Neutral
—
2025-12-02
JPMorgan
2025-12-02
Price Target
—
Neutral
Laidlaw
Hold
$11.00
2025-11-06
Laidlaw
2025-11-06
Price Target
$11.00
Hold
Valuation Metrics
The current forward P/E ratio for Evoke Pharma Inc (EVOK) is -4.72, compared to its 5-year average forward P/E of 6.49.
Alphio AI Price Scenarios for EVOK
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.512-17PRnewswireEvoke Pharma Acquired by QOL Medical for $11.00 Per Share
8.512-17NewsfilterEvoke Pharma Acquired by QOL Medical for $11.00 Per Share
7.012-01GlobenewswireHalper Sadeh LLC Urges Shareholders of EVOK, FSFG, and BRY to Reach Out for Rights Consultation
8.512-01GlobenewswireShareholder Notice: M&A Class Action Firm Ongoing Investigation into the Merger Involving TRUE, BRY, EVOK, and FSFG
7.011-18PRnewswireHalper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to Discuss Their Rights
EVOK FAQ — answered by Alphio AI
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
5 analysts cover EVOK: 5 rate it Buy, 0 Hold and 0 Sell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.